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Background.ObstructiveSleepApneaSyndrome(OSAS)isassociatedwithinﬂammation,butobesitymaybeaconfoundingfactor.
Thus, the aim of this study was to explore diﬀerences in serum levels of inﬂammation markers between obese individuals with or
without OSAS. Methods. Healthy individuals (n = 61) from an outpatient obesity clinic were examined by polysomnography
and blood analysis, for measurement of TNF-α, IL-6, CRP, and ﬁbrinogen levels. According to Apnea-Hypopnea Index (AHI),
participants were divided into two BMI-matched groups: controls (AHI<15/h, n = 23) and OSAS patients (AHI≥15/h, n = 38).
Results. OSAS patients had signiﬁcantly higher TNF-α levels (P<. 001) while no other diﬀerence in the examined inﬂammation
markers was recorded between groups. Overall, TNF-α levels were correlated with neck circumference (P<. 001), AHI (P = .002),
and Oxygen Desaturation Index (P = .002). Conclusions. Obese OSAS patients have elevated TNF-α levels compared to BMI-
matched controls, suggesting a role of OSAS in promoting inﬂammation, possibly mediated by TNF-a.
1.Introduction
Obstructive Sleep Apnea Syndrome (OSAS) is a common
disorder, known to aﬀect about 4% of middle-aged men and
2% of middle-aged women [1]. Patients exhibit repetitive
episodes of partial or complete obstruction of the upper
airway during sleep, ultimately leading to increased respi-
ratory eﬀort, oxyhemoglobin desaturation, sleep fragmenta-
tion, and excessive daytime sleepiness. Increasing evidence
suggests that OSAS is associated with hypertension and
other cardiovascular diseases, metabolic derangement, and
impaired glucose tolerance [2].
Obesityisnotonlyawell-establishedriskfactorforOSAS
[1, 3–6] but also a proinﬂammatory state [7]. In contrast
to earlier theories which considered the adipose tissue as
a sole energy depot, current data demonstrate that it is
an active endocrine organ, releasing a number of bioactive
mediators (adipokines) that modulate blood pressure, lipid-
and glucose-metabolism, atherosclerosis, and inﬂammation
[7–9]. Indeed, macrophages of the adipose tissue secrete
proinﬂammatory cytokines such as Tumor Necrosis Factor-α
(TNF-α) and Interleukin-6 (IL-6) [7, 10].
Similarly, inﬂammation is one of the postulated links
between OSAS and increased cardiovascular morbidity [2].
Indeed, the proinﬂammatory transcription factor NF-κBi s
upregulated in OSAS. This is mediated by the alterations
between hypoxia and reoxygenation, along with sleep depri-
vation. NF-κB plays a key role in inﬂammatory responses,
regulating the expression of inﬂammatory genes [11]. So
far, previous studies, as reviewed by Arnardottir et al. [12],
have recruited subjects from sleep laboratories, attempting
to establish a link between OSAS and inﬂammation by2 Mediators of Inﬂammation
focusing on the markers TNF-α,I L - 6 ,a n dC - r e a c t i v ep r o t e i n
(CRP). However, the contribution of obesity per se in this
inﬂammatory activity has not been adequately determined
[12].
Given that systemic inﬂammation has been demon-
strated in both obesity and OSAS, there may be a possible
interaction between them, rendering extremely diﬃcult the
distinction between inﬂammatory processes attributed to
either of these two conditions. Therefore, the present study
aimed to contribute to the clariﬁcation of such issues. Specif-
ically,it attempted to explore the potential diﬀerences in four
well-established serum inﬂammation markers (TNF-α,I L -
6, CRP, and ﬁbrinogen) between otherwise healthy, obese
subjects with OSAS and their nonapneic obese counterparts.
2. Methods
2.1. Subjects. The present study included sixty-one (50
males and 11 females) subjects. These were consecutively
recruited from the Outpatient Clinic of Obesity, Diabetes
and Metabolism and had consented to be referred for sleep
evaluation. None of them had been previously examined or
had received treatment for obstructive sleep apnea. Body
Mass Index (BMI) was calculated according to the formula
BMI = Weight (in kilograms)/[Height (in meters)]2.A l l
participants had a BMI exceeding 30kg/m2.
Exclusion criteria were as follows: known inﬂammatory
or other chronic disease, diabetes mellitus, cardiovascular
or cerebrovascular, liver, or endocrine disease, hypertension,
chronic use of medication, and smoking. Infection occurring
at the time of the examination was an additional exclusion
criterion. The study was approved by the institutional ethics
committee and all participants had given their informed
consent.
2.2. Study Design
2.2.1. Initial Assessment. Medical history was recorded, and
physical examination was performed. Anthropometrical
data [age, sex, BMI, neck, waist and hip circumference,
and waist-to-hip ratio (WHR)] along with daytime habits
were recorded. Neck circumference was measured at the
cricothyreoid level, waist circumference in the middle
between the 12th rib and the iliac crest, and hip circum-
ference at the level of great trochander by a measure tape.
Blood pressure was recorded as the average of three repeated
measurements in a seated position by an electronic sphyg-
momanometeradaptedtoarmcircumference.Sleepinesswas
evaluated by the Greek version of Epworth Sleepiness Scale
(ESS) [13].
2.2.2. Polysomnography (PSG). All subjects underwent an
attended overnight polysomnography (Somnologica 3.1;
Flaga; Reykjavik, Iceland) using a standard montage of elec-
troencephalogram (EEG), electrooculogram (EOG), elec-
tromyogram (EMG), and electrocardiogram (ECG) signals
together with pulse oximetry and airﬂow, detected using
combined oronasal thermistors. Thoracic cage and abdom-
inal motion were recorded by inductive plethysmography.
Polysomnography was conducted between 22.00 and 06.00
hours. Apneas, hypopneas, and EEG recordings were manu-
allyscoredaccordingtostandardcriteria[14].ApneaHypop-
nea Index (AHI) was calculated by dividing the total number
of apneas and hypopneas to polysomnographically recorded
sleep time, while Oxygen Desaturation Index (ODI) was
calculated by dividing the total number of oxyhaemoglobin
desaturations ≥3% to polysomnographically recorded sleep
time.
Two groups were formed, based on AHI in the polysom-
nographicexamination:OSASpatients(AHI ≥ 15/hour;n =
38) and controls (AHI < 15/hour; n = 23).
2.2.3. Measurement of Cytokines and Biochemical Analysis.
Blood samples were collected between 8 and 9AM following
the polysomnographic examination, while participants were
in a fasting state. After blood collection, serum was frozen
in aliquots at −80
◦C immediately after centrifugation (4◦C,
1600g for 15 minutes). TNF-α a n dI L - 6l e v e l sw e r ed e t e c t e d
with quantitative sandwich enzyme immunoassay technique
(R&D Systems, Minneapolis, USA). Minimum detectable
doses of TNF-α and IL-6 were 1.6pg/mL and 0.7pg/mL,
respectively. High-sensitivity CRP (CRP) was measured by
nephelometric method in an image analyzer (Beckmann
Coulter; California, USA). Fibrinogen levels were measured
by clotting method using a Thrombolyzer B.E. (Behnk
Elektronik GmbH) analyzer.
2.2.4. Statistical Analysis. All continuous variables were
checked for normality (Kolmogorov-Smirnov test). Descrip-
tive results for continuous variables are expressed as mean
± SD. Diﬀerences between individuals with and without
OSAS were examined with independent samples t-test or
Mann-Whitney test, and correlations were explored with
Pearson’s or Spearman correlation, respectively, depending
on the normality of data distribution. The reported P-values
are two tailed. Signiﬁcance was deﬁned at the 5% level (P<
.05). Analysis was performed using SPSS v.15.0 (SPSS Inc.
Chicago, IL).
3. Results
Anthropometric and sleep characteristics of all subjects, as
well as the comparison between the two groups (OSAS
patients and controls), are presented in Table 1. The two
groups were matched in terms of BMI, waist circumfer-
ence and WHR; however, in OSAS patients a signiﬁcantly
greater mean neck circumference was observed. Indices of
lung function, that is, spirometry and arterial blood gases’
analysis,werewithinthenormalrangeinallparticipants,and
blood pressure measurements were below 140/90mmHg. As
expected, characteristics of respiratory function during sleep
in the OSAS group were obviously worse in comparison to
the control group.
OSAS patients had signiﬁcantly higher levels of TNF-α
while no diﬀerence was detected between the two groups in
levels of CRP, IL-6 and ﬁbrinogen (Table 2). Overall, levels
of TNF-α were signiﬁcantly positively correlated with neck
circumference (r = 0.452, P<. 001), AHI (r = 0.391,Mediators of Inﬂammation 3
Table 1: Comparison of anthropometric and sleep characteristics between the two groups.
Total Controls OSAS P-value
(n = 61) (n = 23) (n = 38)
Gender (M/F) 50/11 17/63 3 /5 .353
Age (years) 44.9 ±9.24 3 .7 ±6.74 5 .5 ±10.5 .420
BMI (kg/m2)3 5 .7 ±6.33 4 .5 ±3.73 6 .4 ±7.4 .577
Neck circumference (cm) 42.8 ±3.14 0 .5 ±24 4 .1 ±3 <.001
Waist circumference (cm) 117 ±9.7 114.7 ±7.9 118.4 ±10.5 .147
Hip circumference (cm) 118.7 ±13.7 114.7 ±8.2 121.2 ±15.7 .140
WHR 0.99 ±0.05 1 ±0.03 0.98 ±0.06 .169
Systolic BP (mmHg) 131.1 ±7 131.2 ±6.4 131.1 ±7.4 .864
Diastolic BP (mmHg) 80.4 ±7.98 0 .2 ±7.98 0 .6 ±7.9 .873
FEV1(% pred) 91.1 ±9.79 1 .2 ±8.99 1 ±10.3 .939
FVC (% pred) 89.6 ±10.28 9 ±8.89 0 ±11 .714
PaO2 (mmHg) 82.4 ±6.88 2 .7 ±5.88 2 .2 ±7.5 .786
PaCO2 (mmHg) 38.4 ±2.53 8 .6 ±1.33 8 .2 ±3 .428
pH 7.40 ±0.02 7.40 ±0.01 7.41 ±0.02 .943
ESS 9.9 ±6.26 .6 ±4.61 1 .9 ±6.2 <.001
AHI (/hour) 40 ±34.55 .3 ±3.26 1 ±27 <.001
ODI (/hour) 41.9 ±34.27 .3 ±46 2 .9 ±26.4 <.001
avSpO2 (%) 90.8 ±4.69 3 .4 ±1.48 9 .3 ±5.2 <.001
minSpO2 (%) 75.7 ±11.18 4 .4 ±3.17 0 .4 ±10.8 <.001
t<90 (% TST) 23.6 ±27.83 .3 ±53 6 .3 ±28.7 <.001
Table 2: Comparison of levels of the examined inﬂammatory markers in the two groups.
Total Controls OSAS P-value
(n = 61) (n = 23) (n = 38)
TNF-α (pg/mL) 5.67 ±3.32 3.94 ±1.34 6.72 ±3.72 <.001
CRP (mg/dL) 0.52 ±0.48 0.47 ±0.50 .55 ±0.47 .125
IL-6 (pg/mL) 2.66 ±1.19 2.36 ±1.41 2.73 ±1.14 .465
Fibrinogen (g/L) 2.63 ±0.75 2.7 ±0.65 2.59 ±0.81 .616
P = .002), and ODI (r = 0.384, P = .002) (Figure 1). Inter-
estingly, there was also a small but statistically signiﬁcant
negative correlation of CRP levels with average SpO2 (r =
−0.252, P = .050) and minimum SpO2 (r =− 0.256, P =
.047) during sleep. No other correlation between the levels of
the examined inﬂammation markers and anthropometric or
sleep characteristics of the recruited subjects was observed.
4. Discussion
This study compared obese OSAS subjects with their non-
apneic obese counterparts in terms of four established
serum inﬂammation markers. In comparison to controls
matched for BMI, WHR, and waist circumference, higher
TNF-α levels were revealed in OSAS patients. TNF-α is
an inﬂammatory cytokine that has been found elevated in
patients with sleep apnea [15–17]. It is involved in sleep
regulation [18, 19] and has been positively correlated with
excessive daytime sleepiness, nocturnal sleep disturbance,
and hypoxia [20]. Similar to our ﬁndings, Ciftci et al. [15]
have reported increased TNF-α levels in the presence of
OSAS, and this increase was independent of BMI. However,
they studied only males, whom they recruited from a sleep
disorderscenter,insteadofanobesityclinic[15].Elevationof
TNF-α has also been observed by Minoguchi et al. [16], but,
again,thecomparisonwasbetweenOSASandobesesubjects.
Ryan et al. [17] have demonstrated higher TNF-α levels in
subjects with than in those without OSAS, but they studied
exclusivelymenanddidnotexaminetheimpactofobesityon
TNF-α elevation. Our study diﬀers from the previous works
in two ways. First, we enrolled subjects from an outpatient
clinic of obesity, diabetes, and metabolism. Secondly, all our
subjects were obese. This enabled us to address (for the ﬁrst
time, to the best of our knowledge) the interplay between
obesity and OSAS in the obesity clinic, by comparing OSAS
subjects with their non-apneic counterparts. Hence, our new
message is that TNF-α is increased in the presence of OSAS
among obese subjects.4 Mediators of Inﬂammation
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Figure 1: Association between TNF-α levels and AHI (a), ODI (b), and neck circumference (c) in the study population.
By contrast, there was no diﬀerence between our two
groups in the other three inﬂammatory markers, that is,
CRP, IL-6, and ﬁbrinogen. Prior research has failed to reach
a deﬁnitive conclusion regarding levels of CRP or IL-6 in
OSAS patients. Some authors have reported elevated serum
CRP levels [21–24] while others have come to the opposite
conclusion [25–28]. Similarly, levels of IL-6, the cytokine
inducing the production of CRP, were found elevated in
OSAS patients in numerous studies [15, 20, 24], but most of
them were criticized for the small number of patient series,
the lack of proper match between patients and controls in
BMI, and the inclusion of patients with cardiovascular or
metabolic disorders [29]. On the contrary, other works did
not manage to establish a correlation between OSAS and IL-
6[ 17, 30]. Interestingly, continuous positive airway pressure
therapy (CPAP) has been shown to reduce CRP in patients
with adequate compliance to treatment [31]. It appears,
therefore, that the role of CRP and IL-6 in OSAS is far from
settled and that additional research is required to shed more
light on this issue. In this endeavor for further elucidation
of the role of CRP and IL-6 in OSAS, our report adds that
theseinﬂammatorymarkersarenotincreasedinobeseOSAS
subjects as compared to their non-apneic peers.
Fibrinogen levels are increased in OSAS patients, accord-
ing to previous workers [32–34], indicating a predisposition
for coagulation and atherosclerosis. Conversely, the present
study failed to demonstrate a diﬀerence in ﬁbrinogen levels
between our two groups of obese individuals, suggesting that
the presence of OSAS probably does not play an important
role in the upregulation of ﬁbrinogen levels. Again, the
discrepancy between our results and those of previous
research may be, partly at least, explained by the diﬀerent
setting (patients from obesity clinic versus those from a sleep
unit). Nonetheless, further large-scale studies to re-examine
ﬁbrinogen levels in OSAS would be appreciated.
TNF-α levels showed a signiﬁcant positive correlation
with AHI and ODI. The latter corroborates the ﬁnding by
Ryan et al. [17] where ODI was the strongest predictor ofMediators of Inﬂammation 5
TNF-α levels, indicating the role of intermittent hypoxia
and re-oxygenation in the pathogenesis of inﬂammation
through the activation of NF-κB, a transcription factor
that has an important role in inﬂammatory responses [35].
An additional ﬁnding was the correlation between CRP
levels and indices of nocturnal hypoxia, like average or
minimum SpO2. Taken together, these results suggest that
hypoxia,manifestedasrepetitionofdesaturationsoraslower
levels of average or minimum SpO2, is probably the major
contributor in the activation of inﬂammation in OSAS.
Moreover, a signiﬁcantly greater neck circumference was
noted in OSAS patients, despite the lack of diﬀerence in
other characteristics of obesity, like BMI or WHR. This
observation is common in OSAS patients and many authors
haveemphasizedtheassociationbetweenneckcircumference
and apneas [36]. Additionally, a positive association between
TNF-α levels and neck circumference was observed in our
study population while we did not manage to establish a
correlation between this marker and other indices of obesity.
The limitations of this study may be outlined as follows.
First, the majority of recruited subjects were male. There-
fore, some reservation is needed in applying our ﬁndings
to females. Additionally, although waist circumference is
increasingly recognized to be the best indicator for the
degree of visceral adiposity, we did not employ MRI to
measure directly fat amount and fat distribution, as this
would substantially increase the cost of the study [37, 38].
Thepresentworkmayhavethefollowingpracticalimpli-
cations. Among obese subjects, those with new diagnosis of
OSAS exhibit more pronounced inﬂammation, as evidenced
by the increased levels of TNF-α. Moreover, it is worth
noting that application of CPAP has already been shown to
reduce levels of this cytokine in overt OSAS [39]. Hence,
it is conceivable that inﬂammation, in general, and TNF-
α, in particular, may prove a useful target for therapeutic
intervention inobesepatients. Viceversa,giventhatrepeated
episodes of hypoxia were identiﬁed as a major contributor
in the activation of inﬂammation among newly diagnosed
OSAS patients in this study, one could also argue that
early evaluation of the obese patient for the presence of
OSAS might be anticipated to help towards mitigation of
chronic inﬂammation. Certainly, the interaction between
inﬂammationandOSASinobesepatientsiscomplicatedand
merits further study.
5. Conclusions
The present study shows that, among obese subjects, TNF-α
levels are increased in the presence of OSAS, as compared
to non-apneic BMI-matched controls. Additionally, TNF-
α levels are associated with respiratory disturbance during
sleep, as depicted by AHI and ODI as well as larger neck
circumference, a common feature of OSAS patients. Our
results suggest a role for OSAS in promoting inﬂammation
among obese subjects, possibly mediated by TNF-α. Further
work is now awaited to conﬁrm these ﬁndings in larger
s e r i e s ,a sw e l la st oi n v e s t i g a t et h ep o t e n t i a lr o l eo fe a r l y
therapeutic intervention in the obesity clinic to alleviate
chronic inﬂammation.
Abbreviations
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